Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 64
Filtrar
1.
Exp Biol Med (Maywood) ; 246(21): 2249-2258, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34233524

RESUMEN

After high fractures of the mandibular condyle, the insufficient blood supply to the condyle often leads to poor bone and cartilage repair ability and poor clinical outcome. Parathyroid hormone (PTH) can promote the bone formation and mineralization of mandibular fracture, but its effects on cartilage healing after the free reduction and internal fixation of high fractures of the mandibular condyle are unknown. In this study, a rabbit model of free reduction and internal fixation of high fractures of the mandibular condyle was established, and the effects and mechanisms of PTH on condylar cartilage healing were explored. Forty-eight specific-pathogen-free (SPF) grade rabbits were randomly divided into two groups. In the experimental group, PTH was injected subcutaneously at 20 µg/kg (PTH (1-34)) every other day, and in the control group, PTH was replaced with 1 ml saline. The healing cartilages were assessed at postoperative days 7, 14, 21, and 28. Observation of gross specimens, hematoxylin eosin staining and Safranin O/fast green staining found that every-other-day subcutaneous injection of PTH at 20 µg/kg promoted healing of condylar cartilage and subchondral osteogenesis in the fracture site. Immunohistochemistry and polymerase chain reaction showed that PTH significantly upregulated the chondrogenic genes Sox9 and Col2a1 in the cartilage fracture site within 7-21 postoperative days in the experimental group than those in the control group, while it downregulated the cartilage inflammation gene matrix metalloproteinase-13 and chondrocyte terminal differentiation gene ColX. In summary, exogenous PTH can stimulate the formation of cartilage matrix by triggering Sox9 expression at the early stage of cartilage healing, and it provides a potential therapeutic protocol for high fractures of the mandibular condyle.


Asunto(s)
Cartílago/efectos de los fármacos , Cóndilo Mandibular/lesiones , Fracturas Mandibulares/tratamiento farmacológico , Hormona Paratiroidea/farmacología , Factor de Transcripción SOX9/agonistas , Cicatrización de Heridas/efectos de los fármacos , Animales , Cartílago/fisiología , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/fisiología , Femenino , Fijación Interna de Fracturas/métodos , Masculino , Cóndilo Mandibular/efectos de los fármacos , Cóndilo Mandibular/fisiopatología , Fracturas Mandibulares/cirugía , Metaloproteinasa 13 de la Matriz/metabolismo , Osteogénesis/efectos de los fármacos , Conejos , Factor de Transcripción SOX9/fisiología , Regulación hacia Arriba/efectos de los fármacos
2.
Int Immunopharmacol ; 88: 106870, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32805694

RESUMEN

Osteoarthritis (OA) is a common joint disease affecting millions of elderly people worldwide. However, the mechanism of OA is complicated and remains poorly understood. Thus, a safe and effective therapeutic strategy has yet to be developed. G protein-coupled receptor 17 (GPR17) is an orphan receptor that is widely distributed in the central nervous system (CNS). GPR17 has become a target for the treatment of inflammation in brain diseases. In this study, we demonstrate that GPR17 is expressed in ATDC5 cells and is increased in response to TNF-α exposure. We also found that antagonism of GPR17 with pranlukast significantly inhibited oxidative stress by downregulating the intracellular level of reactive oxygen species (ROS) and increasing the activity of super oxide dismutase (SOD) against TNF-α. Interestingly, treatment with pranlukast prevented TNF-α-induced reduction of type II collagen. Additionally, knockdown of GPR17 with siRNA ameliorated TNF-α-induced loss of type II collagen, suggesting the importance of the role of GPR17 in mediating the impairment of type II collagen. Blockage of GPR17 with pranlukast suppressed the expression of matrix metalloproteinases 3 (MMP-3) and matrix metalloproteinases 13 (MMP-13), which contribute to the degradation of type II collagen. Pranlukast also prevented the activation of the JAK2/STAT1/IRF-1 signaling pathway, thereby suppressing the expression of pro-inflammatory cytokines and enzymes. Furthermore, pranlukast rescued TNF-α-induced reduced SOX-9 expression. Together, our data indicate that GPR17 might be a potential target for the treatment of OA.


Asunto(s)
Cromonas/farmacología , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/metabolismo , Antagonistas de Leucotrieno/farmacología , Proteínas del Tejido Nervioso/antagonistas & inhibidores , Proteínas del Tejido Nervioso/metabolismo , Receptores Acoplados a Proteínas G/antagonistas & inhibidores , Receptores Acoplados a Proteínas G/metabolismo , Animales , Línea Celular Tumoral , Colágeno Tipo II/genética , Técnicas de Silenciamiento del Gen , Factor 1 Regulador del Interferón/metabolismo , Janus Quinasa 2/metabolismo , Metaloproteinasa 13 de la Matriz/metabolismo , Metaloproteinasa 3 de la Matriz/metabolismo , Ratones , Proteínas del Tejido Nervioso/genética , Osteoartritis/prevención & control , Estrés Oxidativo/efectos de los fármacos , Especies Reactivas de Oxígeno/metabolismo , Receptores Acoplados a Proteínas G/genética , Factor de Transcripción SOX9/metabolismo , Factor de Transcripción STAT1/metabolismo , Transducción de Señal/efectos de los fármacos , Superóxido Dismutasa/metabolismo , Factor de Necrosis Tumoral alfa/farmacología
3.
Arthritis Rheumatol ; 72(7): 1123-1133, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32067417

RESUMEN

OBJECTIVE: To investigate the effects of a young systemic environment and growth differentiation factor 11 (GDF-11) on aging cartilage. METHODS: A heterochronic parabiosis model (2-month-old mouse and 12-month-old mouse [Y/O]), an isochronic parabiosis model (12-month-old mouse and 12-month-old mouse [O/O]), and 12-month-old mice alone (O) were evaluated. Knee joints and chondrocytes from old mice were examined by radiography, histology, cell proliferation assays, immunohistochemistry, Western blotting, and quantitative reverse transcriptase-polymerase chain reaction 16 weeks after parabiosis surgery. GDF-11 was injected into 12-month-old mouse joints daily for 16 weeks. Cartilage degeneration, cell proliferation, and osteoarthritis-related gene expression were evaluated. RESULTS: Osteoarthritis Research Society International scores in old mice were significantly lower in the Y/O group than in the O/O and O groups (both P < 0.05). The percentage of 5-ethynyl-2'-deoxyuridine-positive chondrocytes in old mice was significantly higher in the Y/O group than in the other groups (P < 0.05). Type II collagen (CII) and SOX9 messenger RNA levels differed in cartilage from old mice in the Y/O group compared to the O/O and O groups (both P < 0.05). RUNX-2, CX, and matrix metalloproteinase 13 levels were significantly lower in cartilage from old mice in the Y/O group compared to the O/O and O groups (both P < 0.05). Similar results were obtained for protein expression levels and after GDF-11 treatment in vitro and in vivo. Phosphorylated Smad2/3 (pSmad2/3) levels were higher in the recombinant GDF-11-treated group than in the control group. CONCLUSION: A young systemic environment promotes chondrocyte proliferation and cartilage matrix synthesis in old mice. GDF-11, a "young factor," contributes to these effects through the up-regulation of pSmad2/3.


Asunto(s)
Envejecimiento/genética , Proteínas Morfogenéticas Óseas/farmacología , Cartílago Articular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Condrocitos/efectos de los fármacos , Factores de Diferenciación de Crecimiento/farmacología , Osteoartritis de la Rodilla/genética , Parabiosis , Adolescente , Anciano , Envejecimiento/metabolismo , Envejecimiento/patología , Animales , Artroplastia de Reemplazo de Rodilla , Proteínas Morfogenéticas Óseas/metabolismo , Cartílago Articular/metabolismo , Condrocitos/metabolismo , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/genética , Colágeno Tipo II/metabolismo , Colágeno Tipo X/efectos de los fármacos , Colágeno Tipo X/genética , Colágeno Tipo X/metabolismo , Subunidad alfa 1 del Factor de Unión al Sitio Principal/efectos de los fármacos , Subunidad alfa 1 del Factor de Unión al Sitio Principal/genética , Subunidad alfa 1 del Factor de Unión al Sitio Principal/metabolismo , Matriz Extracelular/efectos de los fármacos , Matriz Extracelular/metabolismo , Femenino , Factores de Diferenciación de Crecimiento/metabolismo , Humanos , Técnicas In Vitro , Articulación de la Rodilla , Masculino , Metaloproteinasa 13 de la Matriz/efectos de los fármacos , Metaloproteinasa 13 de la Matriz/genética , Metaloproteinasa 13 de la Matriz/metabolismo , Ratones , Osteoartritis de la Rodilla/metabolismo , Fosforilación , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor de Transcripción SOX9/efectos de los fármacos , Factor de Transcripción SOX9/genética , Factor de Transcripción SOX9/metabolismo , Proteína Smad2/efectos de los fármacos , Proteína Smad2/metabolismo , Proteína smad3/efectos de los fármacos , Proteína smad3/metabolismo , Rodilla de Cuadrúpedos , Adulto Joven
4.
Aging (Albany NY) ; 12(3): 2246-2260, 2020 02 05.
Artículo en Inglés | MEDLINE | ID: mdl-32023553

RESUMEN

The treatment for intervertebral disc degeneration (IDD) has drawn great attention and recent studies have revealed that the p38 MAPK pathway is a potential therapeutic target for delaying the degeneration of intervertebral discs. In this study, we analyzed a nature-derived protein tyrosine kinase inhibitor, Genistein, and its function in delaying IDD in rats both in vitro and in vivo via the p38 MAPK pathway. Nucleus pulposus cells treated with Genistein showed better function compared with untreated cells. Further study revealed that Genistein could play a protective role in IDD by inhibiting phosphorylation of p38, consequently inhibiting the p38 pathway-mediated inflammatory response. The rat IDD model also demonstrated that Genistein could effectively delay the degeneration of intervertebral disc tissue. The current study reveals new biological functions of Genistein, further demonstrates the effects of the p38 MAPK pathway on intervertebral disc degeneration, and deepens our understanding of the treatment and prevention of IDD.


Asunto(s)
Genisteína/farmacología , Degeneración del Disco Intervertebral/metabolismo , Núcleo Pulposo/efectos de los fármacos , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Quinasas p38 Activadas por Mitógenos/efectos de los fármacos , Agrecanos/efectos de los fármacos , Agrecanos/genética , Animales , Supervivencia Celular/efectos de los fármacos , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/genética , Colágeno Tipo X/efectos de los fármacos , Colágeno Tipo X/genética , Inflamación , Interleucina-1beta/efectos de los fármacos , Interleucina-1beta/genética , Interleucina-1beta/metabolismo , Interleucina-1beta/farmacología , Disco Intervertebral/citología , Disco Intervertebral/efectos de los fármacos , Disco Intervertebral/metabolismo , Metaloproteinasa 3 de la Matriz/efectos de los fármacos , Metaloproteinasa 3 de la Matriz/metabolismo , FN-kappa B/efectos de los fármacos , FN-kappa B/metabolismo , Núcleo Pulposo/citología , Núcleo Pulposo/metabolismo , Fosforilación , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Ratas , Transducción de Señal , Factor de Necrosis Tumoral alfa/efectos de los fármacos , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo
5.
Osteoarthritis Cartilage ; 28(5): 698-707, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-31982563

RESUMEN

OBJECTIVE: The alarmin HMGB1 is an endogenous molecule that is released into the extracellular space upon trauma or cell activation. Extracellular HMGB1 initiates innate immune responses and besides mediating inflammation, has osteoclast-activating features and mediates pain, all important features in OA. The aim of this study was to examine the involvement of HMGB1 in experimental OA and to explore the effect of local anti-HMGB1-therapy on disease progression. METHOD: OA was induced in mice by surgical destabilization of knee joints and HMGB1 expression and localization was assessed by immunohistochemistry. For therapy evaluation, HMGB1-neutralizing antibodies were injected intraarticularly, alone or encapsulated in an injectable hyaluronan-based delivery vehicle. Human primary chondrocytes were stimulated with rHMGB1 and analyzed by qPCR and cytometric bead-array. RESULTS: HMGB1 immunostaining of mouse OA joints demonstrated intra- and pericellular expression in chondrocytes, overlapping with proteoglycan depleted areas. Intra-articular injection of anti-HMGB1 antibodies had cartilage-protective effects, comparable to treatment with a TNF inhibitor. Direct and vehicle-based delivery had similar ameliorating effects and the effect of a single, early injection could not be enhanced by repeated injections. In vitro stimulation of chondrocytes with rHMGB1 affected chondrocyte function by inducing protein expression of IL6 and IL8 and downregulating mRNA of COL2A1. CONCLUSIONS: Our results suggest that the alarmin HMGB1 might be a new target for OA therapy development as we could observe an aberrant HMGB1 expression in mouse OA joints, stimulation of chondrocytes with rHMGB1 induced cytokine production and decreased matrix production and finally that HMGB1 blockade suppressed disease progression.


Asunto(s)
Artritis Experimental/metabolismo , Condrocitos/efectos de los fármacos , Proteína HMGB1/metabolismo , Inmunidad Innata , Inflamación/metabolismo , Osteoartritis/metabolismo , Animales , Ligamento Cruzado Anterior/cirugía , Anticuerpos Neutralizantes/administración & dosificación , Anticuerpos Neutralizantes/farmacología , Cartílago Articular/citología , Condrocitos/metabolismo , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/genética , Geles , Proteína HMGB1/antagonistas & inhibidores , Proteína HMGB1/farmacología , Humanos , Ácido Hialurónico , Inmunohistoquímica , Inyecciones Intraarticulares , Interleucina-6/metabolismo , Interleucina-8/efectos de los fármacos , Interleucina-8/metabolismo , Ratones , Osteoartritis/patología , ARN Mensajero/metabolismo
6.
Calcif Tissue Int ; 106(4): 401-414, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-31912171

RESUMEN

The aim of this study was to distinguish the characteristics of intervertebral disc degeneration (IVDD) originating from mechanics imbalance, biology disruption, and their communion, and to develop a composite IVDD model by ovariectomy combined with lumbar facetectomy for mimicking elderly IVDD with osteoporosis and lumbar spinal instability. Mice were randomly divided into four groups and subjected to sham surgery (CON), ovariectomy (OVX), facetectomy (mechanical instability, INS) or their combination (COM), respectively. Radiographical (n = 4) and histological changes (n = 8) of L4/5 spinal segments were analyzed. Tartrate-resistant acid phosphatase (TRAP) staining was conducted to detect osteoclasts, and expression of osterix (OSX), type I collagen (Col I), type II collagen (Col II) and vascular endothelial growth factor (VEGF) were evaluated by immunochemistry. OVX affected the body's metabolism but INS did not, as the body weight increased and uterus weight decreased in OVX and COM mice compared to CON and INS mice. OVX, INS, and COM caused IVDD in various degrees at 12 weeks after surgery. However, the major pathogeneses of OVX- and INS-induced IVDD were different, which focused on endplate (EP) remodeling and annulus fibrosus (AF) collapse, respectively. OVX induced osteopenia of vertebra. In contrast, INS promoted the stress-adaptive increase of subchondral bone trabeculae. The COM produced a reproducible severe IVDD model with characteristics of sparse vertebral trabeculae, cartilaginous EP ossification, subchondral bone sclerosis, fibrous matrix disorder, angiogenesis, disc stiffness, as well as space fusion. Additionally, all groups had elevated bone and cartilage turnover compared with CON group, as the quantity of trap + osteoclasts and the osteogenic OSX expression increased in these groups. Likewise, the VEGF expression levels were similar, accompanied by the altered matrix expression of disc, including the changed distribution and contents of Col II and Col I. The findings suggested that the composite mouse model to some extent could effectively mimic the interactions of biology and mechanics engaged in the onset and natural course of IVDD, which would be more compatible with the IVDD of elderly with vertebral osteoporosis and spinal instability and benefit to further clarify the complicated mechanobiological environment of elderly IVDD progression.


Asunto(s)
Enfermedades Óseas Metabólicas/metabolismo , Degeneración del Disco Intervertebral/cirugía , Vértebras Lumbares/cirugía , Osteoporosis/cirugía , Animales , Conservadores de la Densidad Ósea/farmacología , Enfermedades Óseas Metabólicas/complicaciones , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/metabolismo , Modelos Animales de Enfermedad , Vértebras Lumbares/metabolismo , Ratones , Ratones Endogámicos C57BL , Osteoporosis/complicaciones
7.
Osteoarthritis Cartilage ; 28(3): 344-355, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31326553

RESUMEN

OBJECTIVE: Abnormal remodeling of subchondral bone (SB) induced by estrogen deficiency has been shown to be involved in osteoarthritis (OA). Raloxifene (RAL) is commonly used to treat postmenopausal osteoporosis (OP). However, little is known about its effects on OA combined with estrogen deficiency. This study was performed to evaluate the efficacy of RAL on patella baja-induced patellofemoral joint OA (PFJOA) in an ovariectomized rat model. DESIGN: Patellar ligament shortening (PLS) and ovariectomy (OVX) were performed simultaneously in 3-month-old female Sprague-Dawley rats, which were treated with RAL (10 mg/kg/day) or vehicle at 72 h postoperatively for 10 weeks. PFJOA was assessed by immunohistochemistry (IHC), real-time polymerase chain reaction (PCR), tartrate-resistant acid phosphatase (TRAP) staining, enzyme-linked immunosorbent assay (ELISA), micro-computed tomography (µCT), histomorphology and behavioral analyses. RESULTS: X-ray examinations showed that patella baja was successfully established by PLS. Histomorphological analysis revealed that PFJOA was significantly exacerbated by OVX and markedly alleviated by RAL. Moreover, RAL improved cartilage metabolism by decreasing MMP-13, ADAMTS-4, and caspase-3 and increasing Col-II and aggrecan at both the protein and mRNA levels. Furthermore, RAL markedly improved bone mass and SB microarchitecture and reduced osteoclast numbers and the serum osteocalcin and CTX-I levels. Although RAL showed a trend toward reducing pain sensitivity based on mechanical allodynia testing, this result was not statistically significant. CONCLUSION: These findings demonstrate that RAL treatment retards PFJOA progression in an ovariectomized rat model, suggesting that it may be a potential candidate for amelioration of the progression of PFJOA accompanied by postmenopausal OP.


Asunto(s)
Cartílago Articular/efectos de los fármacos , Osteoartritis de la Rodilla/diagnóstico por imagen , Articulación Patelofemoral/efectos de los fármacos , Clorhidrato de Raloxifeno/farmacología , Moduladores Selectivos de los Receptores de Estrógeno/farmacología , Proteína ADAMTS4/efectos de los fármacos , Proteína ADAMTS4/genética , Proteína ADAMTS4/metabolismo , Agrecanos/efectos de los fármacos , Agrecanos/genética , Agrecanos/metabolismo , Animales , Remodelación Ósea , Huesos/diagnóstico por imagen , Huesos/efectos de los fármacos , Huesos/metabolismo , Huesos/patología , Cartílago Articular/diagnóstico por imagen , Cartílago Articular/metabolismo , Cartílago Articular/patología , Caspasa 3/efectos de los fármacos , Caspasa 3/genética , Caspasa 3/metabolismo , Recuento de Células , Colágeno Tipo I/sangre , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/genética , Colágeno Tipo II/metabolismo , Fémur/diagnóstico por imagen , Fémur/efectos de los fármacos , Fémur/metabolismo , Fémur/patología , Humanos , Inmunohistoquímica , Metaloproteinasa 13 de la Matriz/efectos de los fármacos , Metaloproteinasa 13 de la Matriz/genética , Metaloproteinasa 13 de la Matriz/metabolismo , Osteoartritis de la Rodilla/genética , Osteoartritis de la Rodilla/metabolismo , Osteoartritis de la Rodilla/patología , Osteocalcina/sangre , Osteocalcina/efectos de los fármacos , Osteoclastos/efectos de los fármacos , Osteoporosis Posmenopáusica/tratamiento farmacológico , Osteoporosis Posmenopáusica/metabolismo , Ovariectomía , Rótula/diagnóstico por imagen , Rótula/efectos de los fármacos , Rótula/metabolismo , Rótula/patología , Ligamento Rotuliano/cirugía , Articulación Patelofemoral/diagnóstico por imagen , Articulación Patelofemoral/metabolismo , Articulación Patelofemoral/patología
8.
Osteoarthritis Cartilage ; 27(12): 1811-1821, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31536815

RESUMEN

OBJECTIVE: To explore the effects of Mg2+ on the expression of osteoarthritic markers in human cartilage and synovium tissue explants. To investigate the therapeutic effect of intra-articular injection of Mg2+ in an established rat OA (Osteoarthritis) model of anterior cruciate ligament transection with partial medial meniscectomy (ACLT + PMM). DESIGN: Human cartilage and synovium explants were collected from total knee replacement surgeries and incubated with MgCl2 (20 mmol/L) in vitro. A rat OA model was established by ACLT + PMM surgery in 450-500 g male Sprague Dawley (SD) rats. To select the optimal dose, intra-articular injections of MgCl2 (0.05, 0.5, 5 mol/L) were performed at 4 weeks after the surgery every 3 days for 2 weeks. The effect of optimized MgCl2 was further determined by histology, immunohistochemistry, and quantitative real-time polymerase chain reaction. RESULTS: The expressions of osteoarthritic markers in human cartilage and synovium explants were inhibited by Mg2+in vitro. Immunohistochemical analysis further suggested the inhibitory effects of Mg2+ on the expression of MMP-13 and IL-6 in the human tissue explants. Cartilage degeneration and synovitis in ACLT + PMM rats were significantly improved by intra-articular injections of Mg2+ (0.5 mol/L). Immunohistochemical analysis also showed the regulatory effects of Mg2+ on osteoarthritic markers in both cartilage and synovium in rats, consistent with in vitro results. CONCLUSION: Intra-articular injections of Mg2+ at 0.5 mol/L attenuate the progression of OA in the ACLT + PMM rat model. Such effect was at least in part explained by the promotion of cartilage matrix synthesis and the suppression of synovial inflammation.


Asunto(s)
Cartílago Articular/efectos de los fármacos , Cloruro de Magnesio/farmacología , Metaloproteinasa 13 de la Matriz/efectos de los fármacos , Osteoartritis de la Rodilla/metabolismo , Membrana Sinovial/efectos de los fármacos , Sinovitis/metabolismo , Proteínas ADAMTS/efectos de los fármacos , Proteínas ADAMTS/genética , Proteínas ADAMTS/metabolismo , Anciano , Agrecanos/efectos de los fármacos , Agrecanos/genética , Agrecanos/metabolismo , Animales , Ligamento Cruzado Anterior/cirugía , Artroplastia de Reemplazo de Rodilla , Cartílago Articular/metabolismo , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/genética , Colágeno Tipo II/metabolismo , Modelos Animales de Enfermedad , Femenino , Humanos , Inmunohistoquímica , Técnicas In Vitro , Inyecciones Intraarticulares , Interleucina-1beta/efectos de los fármacos , Interleucina-1beta/genética , Interleucina-1beta/metabolismo , Interleucina-6/genética , Interleucina-6/metabolismo , Masculino , Metaloproteinasa 13 de la Matriz/genética , Metaloproteinasa 13 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/efectos de los fármacos , Metaloproteinasa 9 de la Matriz/genética , Metaloproteinasa 9 de la Matriz/metabolismo , Meniscectomía , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Ratas , Reacción en Cadena en Tiempo Real de la Polimerasa , Membrana Sinovial/metabolismo
9.
J Vet Med Sci ; 81(8): 1211-1218, 2019 Aug 24.
Artículo en Inglés | MEDLINE | ID: mdl-31167981

RESUMEN

Mesenchymal stem cells (MSCs) are proposed to be useful in cartilage regenerative medicine, however, canine MSCs have been reported to show poor chondrogenic capacity. Therefore, optimal conditions for chondrogenic differentiation should be determined by mimicking the developmental process. We have previously established novel and superior canine MSCs named bone marrow peri-adipocyte cells (BM-PACs) and the objective of this study was to evaluate the effects of growth factors required for in vivo chondrogenesis using canine BM-PACs. Spheroids of BM-PACs were cultured in chondrogenic medium containing 10 ng/ml transforming growth factor-ß1 (TGF-ß1) with or without 100 ng/ml bone morphogenetic protein-2 (BMP-2), 100 ng/ml growth differentiation factor-5 (GDF-5) or 100 ng/ml insulin-like growth factor-1 (IGF-1). Chondrogenic differentiation was evaluated by the quantification of glycosaminoglycan and Safranin O staining for proteoglycan production. The expression of cartilage matrix or hypertrophic gene/protein was also evaluated by qPCR and immunohistochemistry. Spheroids in all groups were strongly stained with Safranin O. Although BMP-2 significantly increased glycosaminoglycan production, Safranin O-negative outer layer was formed and the mRNA expression of COL10 relating to cartilage hypertrophy was also significantly upregulated (P<0.05). GDF-5 promoted the production of glycosaminoglycan and type II collagen without increasing COL10 mRNA expression. The supplementation of IGF-1 did not significantly affect cartilaginous and hypertrophic differentiation. Our results indicate that GDF-5 is a useful growth factor for the generation of articular cartilage from canine MSCs.


Asunto(s)
Proteínas Morfogenéticas Óseas/metabolismo , Condrogénesis/efectos de los fármacos , Factores de Diferenciación de Crecimiento/metabolismo , Factor I del Crecimiento Similar a la Insulina/análogos & derivados , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Células Madre Mesenquimatosas/metabolismo , Factor de Crecimiento Transformador beta/metabolismo , Animales , Proteínas Morfogenéticas Óseas/farmacología , Cartílago Articular/efectos de los fármacos , Cartílago Articular/metabolismo , Células Cultivadas/metabolismo , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/metabolismo , Perros , Glicosaminoglicanos/metabolismo , Factores de Diferenciación de Crecimiento/farmacología , Factor I del Crecimiento Similar a la Insulina/metabolismo , Factor I del Crecimiento Similar a la Insulina/farmacología , Péptidos y Proteínas de Señalización Intercelular/farmacología , Células Madre Mesenquimatosas/efectos de los fármacos , Ingeniería de Tejidos , Factor de Crecimiento Transformador beta/farmacología
10.
J Med Ultrason (2001) ; 46(2): 177-186, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30659392

RESUMEN

PURPOSE: Clematis chinensis Osbeck (CCO) is an essential herb that has been shown to promote the biological functions of cartilage cells. In this study, we aimed to explore whether and how low-intensity pulsed ultrasound (LIPUS) enhanced CCO delivery into chondrocytes and stimulated biological activity in vitro. METHODS: Chondrocytes were isolated from knee articular cartilage of 2-week-old rabbits and treated with LIPUS plus CCO or recombinant transforming growth factor beta 1 (TGF-ß1; 0.5 ng/mL), with or without anti-TGF-ß1 antibodies (10 µg/mL), for 3 days. Cell proliferation was assessed by Cell-Counting Kit-8 assays. Immunocytochemistry, western blotting, and quantitative polymerase chain reaction were applied to detect the expression of type II collagen and some molecules in the TGF-ß1 signal pathway. RESULTS: LIPUS plus 0.1 mg/mL CCO solution promoted chondrocyte proliferation and type II collagen and TGF-ß1 expression synergistically in vitro (P < 0.05). In addition, treatment with anti-TGF-ß1 antibodies blocked this effect (P < 0.01), but not completely. CCO plus LIPUS also showed more enhanced effects on promoting TGF-ß receptor II and Smad2 signaling and reducing Smad7 signaling than either intervention separately (P < 0.05). CONCLUSIONS: CCO plus LIPUS promoted extracellular matrix deposition by accelerating the TGF-ß/Smad-signaling pathway in chondrocytes.


Asunto(s)
Condrocitos/efectos de los fármacos , Clematis , Extractos Vegetales/farmacología , Transducción de Señal/fisiología , Proteína Smad2/metabolismo , Factor de Crecimiento Transformador beta1/metabolismo , Ondas Ultrasónicas , Animales , Cartílago Articular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Colágeno Tipo II/efectos de los fármacos , Conejos , Transducción de Señal/efectos de los fármacos , Proteína smad7/metabolismo , Ingeniería de Tejidos
11.
Arch Endocrinol Metab ; 62(4): 438-445, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-30304108

RESUMEN

OBJECTIVE: This study evaluated the effects of combination therapy of curcumin and alendronate on BMD and bone turnover markers in postmenopausal women with osteoporosis. SUBJECTS AND METHODS: In a randomized, double-blind trial study, 60 postmenopausal women were divided into three groups: control, alendronate, and alendronate + curcumin. Each group included 20 patients. Total body, total hip, lumbar spine and femoral neck BMDs were measured by dual-energy X-ray absorptiometry (DXA) at baseline and after 12 months of therapy. Bone turnover markers such as bone-specific alkaline phosphatase (BALP), osteocalcin and C-terminal cross-linking telopeptide of type I collagen (CTx) were measured at the outset and 6 months later. RESULTS: Patients in the control group suffered a significant decrease in BMD and increased bone turnover markers at the end of study. The group treated with only alendronate showed significantly decreased levels of BALP and CTx and increased levels of osteocalcin compared to the control group. The alendronate group also showed significant increases in the total body, total hip, lumbar spine and femoral neck BMDs at the end of study compared to the control group. In the curcumin + alendronate group, BALP and CTx levels decreased and osteocalcin levels increased significantly at the end of study compared to the control and alendronate groups. BMD indexes also increased in four areas significantly at the end of study compared to the control and alendronate groups. CONCLUSION: The combination of curcumin and alendronate has beneficial effects on BMD and bone turnover markers among postmenopausal women with osteoporosis. Arch Endocrinol Metab. 2018;62(4):438-45.


Asunto(s)
Alendronato/farmacología , Conservadores de la Densidad Ósea/farmacología , Densidad Ósea/efectos de los fármacos , Curcumina/farmacología , Osteoporosis Posmenopáusica/metabolismo , Anciano , Fosfatasa Alcalina/análisis , Fosfatasa Alcalina/efectos de los fármacos , Remodelación Ósea/efectos de los fármacos , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/orina , Método Doble Ciego , Quimioterapia Combinada/métodos , Femenino , Humanos , Persona de Mediana Edad , Osteocalcina/análisis , Osteocalcina/efectos de los fármacos , Fragmentos de Péptidos/efectos de los fármacos , Fragmentos de Péptidos/orina
12.
Arch. endocrinol. metab. (Online) ; 62(4): 438-445, July-Aug. 2018. tab, graf
Artículo en Inglés | LILACS | ID: biblio-950087

RESUMEN

ABSTRACT Objective: This study evaluated the effects of combination therapy of curcumin and alendronate on BMD and bone turnover markers in postmenopausal women with osteoporosis. Subjects and methods: In a randomized, double-blind trial study, 60 postmenopausal women were divided into three groups: control, alendronate, and alendronate + curcumin. Each group included 20 patients. Total body, total hip, lumbar spine and femoral neck BMDs were measured by dual-energy X-ray absorptiometry (DXA) at baseline and after 12 months of therapy. Bone turnover markers such as bone-specific alkaline phosphatase (BALP), osteocalcin and C-terminal cross-linking telopeptide of type I collagen (CTx) were measured at the outset and 6 months later. Results: Patients in the control group suffered a significant decrease in BMD and increased bone turnover markers at the end of study. The group treated with only alendronate showed significantly decreased levels of BALP and CTx and increased levels of osteocalcin compared to the control group. The alendronate group also showed significant increases in the total body, total hip, lumbar spine and femoral neck BMDs at the end of study compared to the control group. In the curcumin + alendronate group, BALP and CTx levels decreased and osteocalcin levels increased significantly at the end of study compared to the control and alendronate groups. BMD indexes also increased in four areas significantly at the end of study compared to the control and alendronate groups. Conclusion: The combination of curcumin and alendronate has beneficial effects on BMD and bone turnover markers among postmenopausal women with osteoporosis. Arch Endocrinol Metab. 2018;62(4):438-45


Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Anciano , Densidad Ósea/efectos de los fármacos , Osteoporosis Posmenopáusica/metabolismo , Alendronato/farmacología , Curcumina/farmacología , Conservadores de la Densidad Ósea/farmacología , Fragmentos de Péptidos/efectos de los fármacos , Fragmentos de Péptidos/orina , Osteocalcina/análisis , Osteocalcina/efectos de los fármacos , Método Doble Ciego , Remodelación Ósea/efectos de los fármacos , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/orina , Quimioterapia Combinada/métodos , Fosfatasa Alcalina/análisis , Fosfatasa Alcalina/efectos de los fármacos
13.
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi ; 32(10): 1340-1345, 2018 10 15.
Artículo en Chino | MEDLINE | ID: mdl-30600669

RESUMEN

Objective: To investigate the mechanism of magnesium sulfate in protecting rabbit cartilage by initiating autophagy. Methods: Twenty-four adult female New Zealand rabbits were used to prepare post-traumatic osteoarthritis (PTOA) models by anterior cruciate ligament transection. Then, the PTOA models were randomly divided into PTOA group, distilled water group, and magnesium sulfate group, with 8 rabbits in each group. Immediately after operation, the distilled water group and the magnesium sulfate group were injected with 0.5 mL distilled water and 20 mmol/L magnesium sulfate solution in the joint cavity 3 times a week for 4 weeks, respectively. The PTOA group was not treated. The general condition of the animals was observed after operation. After 4 weeks, the expressions of tumor necrosis factor α (TNF-α) and collagen typeⅡ in the joint fluid and the expression of collagen type Ⅱ in venous blood were detected by ELISA assay. The protein expressions of transient receptor potential channel vanilloid 5 (TRPV5) and microtubule associated protein 1 light chain 3 (LC3; LC3-Ⅱ/LC3-Ⅰ) in femoral cartilage were detected by Western blot. The mRNA expressions of interleukin 1ß (IL-1ß), TNF-α, matrix metalloproteinases 3 (MMP-3) in synovial tissue and collagen type Ⅱ, Aggrecan (AGN), SOX9 in cartilage tissue were detected by real-time fluorescence quantitative PCR. Cartilage tissue sections were stained with HE staining, Masson staining, and Alcian blue staining and scored according to the modified histological osteoarthritis (OA) score. Results: All animals survived until the experiment was completed. Compared with the other two groups, the expression of TNF-α in joint effusion and collagen type Ⅱ in joint effusion and venous blood were decreased in magnesium sulfate group; the protein expression of TRPV5 decreased, and the ratio of LC3-Ⅱ/LC3-Ⅰ increased significantly; the mRNA expressions of IL-1ß, TNF-α, and MMP-3 in synovial tissue were decreased, and the mRNA expressions of collagen type Ⅱ, AGN, and SOX9 in cartilage tissue were increased; OA scores also decreased significantly. All differences were statistically significant ( P<0.05). There was no significant difference in the above indicators between the PTOA group and the distilled water group ( P>0.05). Conclusion: Intra-articular injection of magnesium sulfate can reduce intra-articular inflammation, reduce the loss of collagen type Ⅱ and AGN, and is beneficial to cartilage regeneration in rabbits. The mechanism may be related to the initiation of chondroautophagy by inhibiting the calcium channel TRPV5.


Asunto(s)
Agrecanos/efectos de los fármacos , Ligamento Cruzado Anterior/efectos de los fármacos , Autofagia , Cartílago Articular/efectos de los fármacos , Colágeno Tipo II/efectos de los fármacos , Sulfato de Magnesio/farmacología , Osteoartritis/tratamiento farmacológico , Animales , Modelos Animales de Enfermedad , Femenino , Inyecciones Intraarticulares , Interleucina-1beta/metabolismo , Sulfato de Magnesio/administración & dosificación , Conejos , Líquido Sinovial , Membrana Sinovial , Factor de Necrosis Tumoral alfa/metabolismo
14.
Bratisl Lek Listy ; 118(10): 591-597, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29198125

RESUMEN

BACKGROUND: Due to very sluggish turnover at the molecular and cellular level, the healing of chondral damages has been considered difficult. In the current study, the effects of the Kartogenin, a small heterocyclic molecule on chondrogenic differentiation of stem cells was compared to TGF-ß3. METHODS: Human Adipose-Derived Stem Cells were extracted during an elective surgery. Cell viability was estimated by MTT assay, differentiated cells evaluated by histological and immunohistochemical techniques. Expression of cartilage specific genes (SOX9, Aggrecan, type II and X collagens) assessed by real-time PCR. RESULTS: The real-time PCR assay has revealed the expression of gene marker of chondrogenesis, SOX9, Aggrecan and type II collagen, both in Kartogenin and TGFß3 groups compared to the control group, significantly (p < 0.05). A low expression level of collagen type X as a hypertrophic marker was seen in cartilage produced by using Kartogenin. Meanwhile, the level of type X collagen protein in Kartogenin group was significantly decreased (p > 0.05) compared to TGF-ß3 group. CONCLUSION: Kartogenin was suitable for successful chondrogenic differentiation of human adipose- derived stem cells and a suppressor of the consequent hypertrophy (Tab. 1, Fig. 5, Ref. 31).


Asunto(s)
Anilidas/farmacología , Condrogénesis/efectos de los fármacos , Ácidos Ftálicos/farmacología , Células Madre/efectos de los fármacos , Factor de Crecimiento Transformador beta3/farmacología , Tejido Adiposo/citología , Agrecanos/efectos de los fármacos , Agrecanos/genética , Cartílago , Diferenciación Celular/efectos de los fármacos , Células Cultivadas , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/genética , Colágeno Tipo X/efectos de los fármacos , Colágeno Tipo X/genética , Fibrina , Humanos , Reacción en Cadena en Tiempo Real de la Polimerasa , Factor de Transcripción SOX9/efectos de los fármacos , Factor de Transcripción SOX9/genética , Andamios del Tejido
15.
J Healthc Eng ; 2017: 9747264, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29065675

RESUMEN

This study was undertaken to determine the effects of IL-1ß and TGF-ß1 on the expression of differentiation-associated genes in chondrocytes in vitro. Rat costal chondrocytes were exposed to different concentrations of IL-1ß and TGF-ß1 for 48 h and tested for gene expression. IL-1ß increased the expression of aggrecanase-1 and aggrecanase-2 and decreased the content of aggrecan and collagen II. Low concentration of TGF-ß1 decreased the expression of aggrecan and collagen II and increased the expression of aggrecanase-2. However, the level of aggrecanase-1 was significantly elevated in the presence of high concentration of TGF-ß1. IL-1ß and TGF-ß1 show the ability to modulate the production of aggrecan and collagen II in chondrocytes in vitro.


Asunto(s)
Condrocitos/efectos de los fármacos , Condrocitos/inmunología , Expresión Génica/efectos de los fármacos , Interleucina-1beta/farmacología , Factor de Crecimiento Transformador beta1/farmacología , Agrecanos/efectos de los fármacos , Animales , Colágeno Tipo II/efectos de los fármacos , Ratas , Ratas Sprague-Dawley
16.
Osteoarthritis Cartilage ; 25(12): 1952-1961, 2017 12.
Artículo en Inglés | MEDLINE | ID: mdl-28964890

RESUMEN

OBJECTIVE: To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABT-981, a human dual variable domain immunoglobulin simultaneously targeting interleukin (IL)-1α and IL-1ß, in patients with knee osteoarthritis (OA). METHOD: This was a randomized, double-blind, placebo-controlled, single-center study of multiple subcutaneous (SC) injections of ABT-981 in patients with mild-to-moderate OA of the knee (NCT01668511). Three cohorts received ABT-981 (0.3, 1, or 3 mg/kg) or placebo every other week for a total of four SC injections, and one cohort received ABT-981 (3 mg/kg) or placebo every 4 weeks for a total of three SC injections. Assessment of safety and tolerability were the primary objectives. A panel of serum and urine biomarkers of inflammation and joint degradation were evaluated. RESULTS: A total of 36 patients were randomized (ABT-981, n = 28; placebo, n = 8); 31 (86%) completed the study. Adverse event (AE) rates were comparable between ABT-981 and placebo (54% vs 63%). The most common AE reported with ABT-981 vs placebo was injection site erythema (14% vs 0%). ABT-981 significantly reduced absolute neutrophil count and serum concentrations of IL-1α/IL-1ß, high-sensitivity C-reactive protein, and matrix metalloproteinase (MMP)-derived type 1 collagen. Serum concentrations of MMP-derived type 3 collagen and MMP-degraded C-reactive protein demonstrated decreasing trends with ABT-981. Antidrug antibodies were found in 37% of patients but were not associated with the incidence or severity of AEs. CONCLUSION: ABT-981 was generally well tolerated in patients with knee OA and engaged relevant tissue targets, eliciting an anti-inflammatory response. Consequently, ABT-981 may provide clinical benefit to patients with inflammation-driven OA.


Asunto(s)
Inmunoglobulinas/uso terapéutico , Interleucina-1alfa/antagonistas & inhibidores , Interleucina-1beta/antagonistas & inhibidores , Osteoartritis de la Rodilla/tratamiento farmacológico , Anciano , Agrecanos/efectos de los fármacos , Agrecanos/metabolismo , Proteína C-Reactiva/efectos de los fármacos , Proteína C-Reactiva/metabolismo , Proteína de la Matriz Oligomérica del Cartílago/efectos de los fármacos , Proteína de la Matriz Oligomérica del Cartílago/metabolismo , Citrulinación , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo I/metabolismo , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/metabolismo , Colágeno Tipo III/efectos de los fármacos , Colágeno Tipo III/metabolismo , Eritema , Femenino , Humanos , Inmunoglobulinas/farmacología , Reacción en el Punto de Inyección , Inyecciones Subcutáneas , Interleucina-1beta/efectos de los fármacos , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Neutrófilos/citología , Osteoartritis de la Rodilla/metabolismo , Péptidos/efectos de los fármacos , Péptidos/metabolismo , Índice de Severidad de la Enfermedad , Factor A de Crecimiento Endotelial Vascular/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular/metabolismo , Vimentina/efectos de los fármacos , Vimentina/metabolismo
17.
Osteoarthritis Cartilage ; 25(12): 2119-2126, 2017 12.
Artículo en Inglés | MEDLINE | ID: mdl-28882751

RESUMEN

OBJECTIVES: Develop a species-specific ELISA for a neo-epitope generated by cathepsin K cleavage of equine type II collagen to: (1) measure cartilage type II collagen degradation by cathepsin K in vitro, (2) identify cytokines that upregulate cathepsin K expression and (3) compare cathepsin K with matrix metalloproteinase (MMP) collagenase activity in stimulated cartilage explants and freshly isolated normal and osteoarthritic (OA) articular cartilages. DESIGN: A new ELISA (C2K77) was developed and tested by measuring the activity of exogenous cathepsin K on equine articular cartilage explants. The ELISA was then employed to measure endogenous cathepsin K activity in cultured cartilage explants with or without stimulation by interleukin-1 beta (IL-1ß), tumour necrosis-alpha (TNF-α), oncostatin M (OSM) and lipopolysaccharide (LPS). Cathepsin K activity in cartilage explants (control and osteoarthritic-OA) and freshly harvested cartilage (control and OA) was compared to that of MMPs employing C2K77 and C1,2C immunoassays. RESULTS: The addition of Cathepsin K to normal cartilage caused a significant increase (P < 0.01) in the C2K77 epitope release. Whereas the content of C1,2C, that reflects MMP collagenase activity, was increased in media by the addition to cartilage explants of TNF-α and OSM (P < 0.0001) or IL-1ß and OSM (P = 0.002), no change was observed in C2K77 which also unchanged in OA cartilages compared to normal. CONCLUSIONS: The ELISA C2K77 measured the activity of cathepsin K in equine cartilage which was unchanged in OA cartilage. Cytokines that upregulate MMP collagenase activity had no effect on endogenous cathepsin K activity, suggesting a different activation mechanism that requires further study.


Asunto(s)
Cartílago Articular/metabolismo , Catepsina K/metabolismo , Colágeno Tipo II/metabolismo , Articulación Metacarpofalángica/metabolismo , Osteoartritis/metabolismo , Animales , Cartílago Articular/efectos de los fármacos , Cartílago Articular/patología , Estudios de Casos y Controles , Catepsina K/efectos de los fármacos , Colágeno Tipo II/efectos de los fármacos , Citocinas/farmacología , Ensayo de Inmunoadsorción Enzimática , Caballos , Técnicas In Vitro , Interleucina-1beta/farmacología , Lipopolisacáridos/farmacología , Articulación Metacarpofalángica/efectos de los fármacos , Articulación Metacarpofalángica/patología , Oncostatina M/farmacología , Factor de Necrosis Tumoral alfa/farmacología
18.
Osteoarthritis Cartilage ; 25(11): 1858-1867, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-28823647

RESUMEN

OBJECTIVE: Fibroblast growth factor (FGF) 18 has been shown to increase cartilage volume when injected intra-articularly in animal models of osteoarthritis (OA) and in patients with knee OA (during clinical development of the recombinant human FGF18, sprifermin). However, the exact nature of this effect is still unknown. In this study, we aimed to investigate the effects of sprifermin at the cellular level. DESIGN: A combination of different chondrocyte culture systems was used and the effects of sprifermin on proliferation, the phenotype and matrix production were evaluated. The involvement of MAPKs in sprifermin signalling was also studied. RESULTS: In monolayer, we observed that sprifermin promoted a round cell morphology and stimulated both cellular proliferation and Sox9 expression while strongly decreasing type I collagen expression. In 3D culture, sprifermin increased the number of matrix-producing chondrocytes, improved the type II:I collagen ratio and enabled human OA chondrocytes to produce a hyaline extracellular matrix (ECM). Furthermore, we found that sprifermin displayed a 'hit and run' mode of action, with intermittent exposure required for the compound to fully exert its anabolic effect. Finally, sprifermin appeared to signal through activation of ERK. CONCLUSIONS: Our results indicate that intermittent exposure to sprifermin leads to expansion of hyaline cartilage-producing chondrocytes. These in vitro findings are consistent with the increased cartilage volume observed in the knees of OA patients after intra-articular injection with sprifermin in clinical studies.


Asunto(s)
Proliferación Celular/efectos de los fármacos , Condrocitos/efectos de los fármacos , Matriz Extracelular/efectos de los fármacos , Factores de Crecimiento de Fibroblastos/farmacología , Cartílago Hialino/efectos de los fármacos , Animales , Técnicas de Cultivo de Célula , Condrocitos/metabolismo , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo I/metabolismo , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/metabolismo , Matriz Extracelular/metabolismo , Humanos , Cartílago Hialino/metabolismo , Técnicas In Vitro , Proteínas Quinasas Activadas por Mitógenos/efectos de los fármacos , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Proteínas Recombinantes/farmacología , Factor de Transcripción SOX9/efectos de los fármacos , Factor de Transcripción SOX9/metabolismo , Transducción de Señal/efectos de los fármacos , Porcinos
19.
Osteoarthritis Cartilage ; 25(11): 1912-1921, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-28823646

RESUMEN

OBJECTIVE: To downregulate the expression of leptin receptor functional isoform (Ob-Rb) on chondrocytes using lentiviral vector-mediated short-hairpin RNA (LV-shRNA) and to determine its effects on cartilage degeneration. METHOD: In vitro, quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting were performed to select an optimal Ob-Rb LV-shRNA (LV-shRNA3) and to determine its effects on nine OA-related mediators in cultured rat chondrocytes. In vivo, an OA model was surgically induced in the right knees of rats, and LV-shRNA3, lentiviral vector-mediated non-targeting control sequence (LV-NTC) or phosphate buffered saline was injected into the joints. Osteoarthritis Research Society International (OARSI) scoring was performed to assess cartilage degeneration, and immunohistochemistry was performed to evaluate OA-related mediator expression in the above groups. RESULTS: Ob-Rb expression was significantly downregulated by LV-shRNA3 in cultured chondrocytes. In conjunction with Ob-Rb downregulation, the expression levels of pro-inflammatory mediators (TNF-α, IL-1ß and IL-6) and catabolic mediators (ADAMTS-5, MMP-9, NOS-2 and COX-2) were also significantly decreased, and the expression levels of anabolic type II collagen were significantly increased. The in vivo study results showed that OARSI scores were significantly decreased by LV-shRNA3. Immunohistochemistry analysis demonstrated that Ob-Rb expression levels on chondrocytes were significantly downregulated by LV-shRNA3. In conjunction with Ob-Rb downregulation, ADAMTS-5 and MMP-9 expression levels were also significantly decreased, and type II collagen expression levels were increased. CONCLUSION: These results indicate that LV-shRNA3-mediated Ob-Rb downregulation on chondrocytes inhibits cartilage degeneration in a rat model of OA, suggesting that Ob-Rb may be a novel target in the treatment of OA.


Asunto(s)
Cartílago Articular/efectos de los fármacos , Condrocitos/efectos de los fármacos , Osteoartritis de la Rodilla/metabolismo , ARN Interferente Pequeño/farmacología , Receptores de Leptina/genética , Proteína ADAMTS5/efectos de los fármacos , Proteína ADAMTS5/metabolismo , Animales , Western Blotting , Cartílago Articular/metabolismo , Condrocitos/metabolismo , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/metabolismo , Ciclooxigenasa 2/efectos de los fármacos , Ciclooxigenasa 2/metabolismo , Modelos Animales de Enfermedad , Regulación hacia Abajo , Técnicas de Silenciamiento del Gen , Vectores Genéticos , Técnicas In Vitro , Interleucina-1beta/efectos de los fármacos , Interleucina-1beta/metabolismo , Interleucina-6/metabolismo , Lentivirus , Masculino , Metaloproteinasa 9 de la Matriz/efectos de los fármacos , Metaloproteinasa 9 de la Matriz/metabolismo , Óxido Nítrico Sintasa de Tipo II/efectos de los fármacos , Óxido Nítrico Sintasa de Tipo II/metabolismo , Isoformas de Proteínas , Ratas , Ratas Sprague-Dawley , Reacción en Cadena en Tiempo Real de la Polimerasa , Receptores de Leptina/metabolismo , Factor de Necrosis Tumoral alfa/efectos de los fármacos , Factor de Necrosis Tumoral alfa/metabolismo
20.
Chin J Dent Res ; 20(3): 125-135, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28808696

RESUMEN

OBJECTIVE: To explore the effect of long-term stress on the temporomandibular joint (TMJ) condyle and its possible underlying mechanism. METHODS: A 12-week, chronic unpredictable mild stress (CUMS) model was used to induce long-term psychological stress in rats. Rats were randomly divided into control group (CONT), chronic unpredictable mild stress group (CUMS) and chronic unpredictable mild stress with fluoxetine treatment group (CUMS + DT) (n = 30 per group). A 5 mg/kg dose of fluoxetine was intraperitoneally injected daily 0.5 h before stress. A sucrose preference test, plasma corticosterone test and open-field test were performed to verify the feasibility of the CUMS model. Histopathology was used to observe the pathological changes of condyle. The expression levels of inflammatory cytokines, matrix metalloproteases (MMPs) and extracellular matrix (ECM) were measured by real-time polymerase chain reaction, western blotting and immunohistochemistry. RESULTS: At 8 and 12 weeks after exposure to CUMS, the rats showed higher plasma corticosterone than the control rats. Additionally, for the open-field test, the rats exposed to CUMS spent more time in the centre zone and moved a shorter distance than the control and drug treatment rats. In addition, pathological changes in the condylar cartilage occurred in the 8-week CUMS subgroup and were more obvious in the 12-week CUMS subgroup. The CUMS caused an increase in the secretion of inflammatory cytokines, imbalanced expression of MMPs and tissue inhibitor of metalloproteinase-1 and accelerated degradation of ECM in condylar cartilage in a time-dependent manner. CONCLUSION: Osteoarthritis-like lesions can be caused by long-term CUMS in the mandibular condyles, which suggests that the imbalance in chondrocyte-secreted regulatory factors within the cartilage of the TMJ may play an important role in cartilage injury induced by psychological stress.


Asunto(s)
Cartílago Articular/metabolismo , Matriz Extracelular/metabolismo , Cóndilo Mandibular/metabolismo , Estrés Psicológico/metabolismo , Agrecanos/efectos de los fármacos , Agrecanos/genética , Agrecanos/metabolismo , Animales , Conducta Animal , Western Blotting , Cartílago Articular/efectos de los fármacos , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/genética , Colágeno Tipo II/metabolismo , Corticosterona/metabolismo , Citocinas/metabolismo , Ensayo de Inmunoadsorción Enzimática , Matriz Extracelular/efectos de los fármacos , Fluoxetina/farmacología , Inmunohistoquímica , Masculino , Cóndilo Mandibular/efectos de los fármacos , Metaloproteinasa 3 de la Matriz/efectos de los fármacos , Metaloproteinasa 3 de la Matriz/genética , Metaloproteinasa 3 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/efectos de los fármacos , Metaloproteinasa 9 de la Matriz/genética , Metaloproteinasa 9 de la Matriz/metabolismo , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Reacción en Cadena en Tiempo Real de la Polimerasa , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Estrés Psicológico/genética , Articulación Temporomandibular , Inhibidor Tisular de Metaloproteinasa-1/efectos de los fármacos , Inhibidor Tisular de Metaloproteinasa-1/genética , Inhibidor Tisular de Metaloproteinasa-1/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...